First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin 1 Expanded reimbursement facilitates wider access to continuous ...
Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people 3 and often accompanied by cardiovascular complications. 4 People with Type 1 and Type 2 diabetes are 2 ...
Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...
Tandem’s Control-IQTM hybrid closed-loop technology now integrates with the 15-day continuous glucose monitoring sensor. This ad will auto-close in 10 seconds ...
Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
The diabetes management space just got a whole lot more interesting. FDA has cleared Abbott's FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous monitoring sensors for integration with ...
Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback